LumaCina - Bridgewest Perth Pharma
Mark Weir-Smith is currently the Senior Vice President Quality Operations and Regulatory Affairs at NovaCina, LumaCina, and Bridgewest Perth Pharma. Prior to this, Mark held roles such as Medical Assessor at the National Association of Testing Authorities, WA & NT General Practice Business Operations Leader at Western Diagnostic Pathology, Quality Operations and Regulatory Affairs Site Leader at Pfizer, and Regional Manager at the Australian Red Cross. Mark has also served as Vice President and Board Member at the ISPE Australasia Affiliate. Mark has a background in Science and Medical Science from Curtin University, with additional education in Business Organisational Leadership from Harvard Business School.
This person is not in any teams
LumaCina - Bridgewest Perth Pharma
Empowering Health Worldwide: Welcome to Lumacina, Your Global Hub for Cutting-Edge Sterile Injectable Solutions! As proud distributors of a dynamic portfolio we ensure top-notch quality. Our futuristic R&D is propelling a wave of innovation, set to revolutionize regulated and semi-regulated markets across the globe. From multi-dose vials to blow-fill-seal presentations and cytotoxic products, we're the pioneers of diverse dosage forms. Bridgewest Group Fueling Innovation: Lumacina, a Luminary in Bridgewest Perth Pharma, a Proud Entity of Bridgewest Group. Unleashing Potential with NovaCina and LumaCina, We're Transforming the Future of Healthcare."